Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06994949 · ClinicalTrials.gov registry record · Phase 1
Assessing CSF Flow Dynamics in Pediatric Hemorrhagic Hydrocephalus
A Phase 1 study of Post-hemorrhagic Hydrocephalus (PHH), sponsored by Eva Sevick.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06994949: Recruiting Phase 1 study of Post-hemorrhagic Hydrocephalus (PHH), sponsored by Eva Sevick.
NCT06994949 is a Phase 1 study of Post-hemorrhagic Hydrocephalus (PHH) that is actively recruiting participants, run by Eva Sevick. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06994949, a Phase 1 study of Post-hemorrhagic Hydrocephalus (PHH), is actively recruiting participants, sponsored by Eva Sevick.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ventricular microdosing of indocyanine green (ICG) in order to assess cerebrospinal fluid (CSF) ventricular dynamics and extracranial CSF outflow using fluorescent Cap-based Transcranial Optical Tomography (fCTOT) and Near-InfraRed Fluorescent (NIRF) imaging and to evaluate inflammation markers of the CSF and to correlate with CSF ventricular dynamics, extracranial outflow into the lymphatics, ventriculomegaly, and patient's clinical outcome in order to understand how inflammation may impact that status of extracranial outflow.
Conditions Studied
Interventions
- DRUG ICG
- DEVICE fCTOT cap
- DEVICE NIRF planar imaging
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2029-01-03 |
| Phase | Phase 1 |
What NCT06994949 shows while recruiting
NCT06994949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Post-hemorrhagic Hydrocephalus (PHH) appearing as the primary indexed condition, and to 3 interventions - of which ICG is the first listed.
NCT06994949 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06994949 about?
NCT06994949 is a clinical study titled "Assessing CSF Flow Dynamics in Pediatric Hemorrhagic Hydrocephalus". The purpose of this study is to evaluate the safety and efficacy of ventricular microdosing of indocyanine green (ICG) in order to assess cerebrospinal fluid (CSF) ventricular dynamics and extracranial CSF outflow using fluorescent Cap-based Transcranial Optical Tomography (fCTOT) and Near-InfraRed ...
What is the current status of trial NCT06994949?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-01-14. Estimated completion is 2029-01-03.
What conditions does trial NCT06994949 study?
This clinical trial studies the following conditions: Post-hemorrhagic Hydrocephalus (PHH).
What interventions are being tested in trial NCT06994949?
The interventions under investigation include: ICG (DRUG), fCTOT cap (DEVICE), NIRF planar imaging (DEVICE).
Who is sponsoring clinical trial NCT06994949?
This trial is sponsored by Eva Sevick, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06994949 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06994949's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI